Ultragenyx Pharma (RARE), GeneTx Report Investigational New Drug Application Active for GTX-102 in Patients with Angelman Syndrome

Go back to Ultragenyx Pharma (RARE), GeneTx Report Investigational New Drug Application Active for GTX-102 in Patients with Angelman Syndrome
ULTRAGENYX PHARM (NASDAQ: RARE) Delayed: 14.51 +0.01 (0.07%)
Previous Close $14.50    52 Week High $117.12 
Open $14.79    52 Week Low $46.52 
Day High $15.07    P/E N/A 
Day Low $14.07    EPS $-1.97 
Volume 13,226,705